Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting;Orta Prevalansli Bölgede Akciǧer ve Akciǧer DIŞI Tüberküloz Tanisinda Xpert MTB/RIF Testinin Deǧerlendirilmesi

Mikrobiyoloji Bulteni

Volumn 48, Issue 2, 2014, Pages 223-232

  Özkütük, Nuri ^a   Sürücüog̈lu, Süheyla ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Mycobacterium tuberculosis; Rifampicin resistance; Tuberculosis; Xpert MTB RIF

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD; TUBERCULOSIS; TURKEY (REPUBLIC);

ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; TURKEY;

EID: 84901476498     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: 10.5578/mb.7456     Document Type: Article

References (24)

1. World Health Organization. Global Tuberculosis Report 2013. WHO, Geneva. Available at: http://apps.who. int/iris/bitstream/10665/91355/1 /9789241564656-eng.pdf?ua=1
2. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement 2011, Geneva. Available at: http://whqlibdoc.who.int/publications/2011/9789241501545-eng.pdf?ua=1
3. Pai M, Palamountain KM. New tuberculosis technologies: challenges for retooling and scale-up. Int J Tuberc Lung Dis 2012; 16(10): 1281-90.
4. Wilson ML. Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. Clin Infect Dis 2011; 52(11): 1350-5.
5. Van Rie A, Page-Shipp L, Scott L Sanne I, Stevens W. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010; 10(7): 937-46.
6. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012; 64(6): 580-8.
7. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010; 16(3): 271-84.
8. WHO. Framework for implementing new tuberculosis diagnostics. World Health Organization, 2011, Geneva, Switzerland.
9. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuber-culosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J Clin Microbiol 2011; 49(12): 4138-41.
10. Ciftci IH, Aslan MH, Asik G. Evaluation of Xpert MTB/RIF results for the detection of Mycobacterium tuberculosis in clinical samples. Mikrobiyol Bul 2011; 45(1): 43-7.
11. Yoon C, Cattamanchi A. Utility of newer and novel tools for the diagnosis of tuberculosis. South African Respiratory Journal 2013; 18(3): 83-4.
12. WHO, Expert Group Meeting Report, 2013. The use of the XPERT MTB/RIF assay for the detection of pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children. World Health Organization, 2013, Geneva, Switzerland.
13. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME; Evidence for Scale-up Group. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205 (Suppl 2): S191-8.
14. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2012; 74(2): 207-9.
15. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8(7): e1001067.
16. Kurbatova EV, Kaminski DA, Erokhin W, et al. Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 2013; 32(6):735-43.
17. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363(11): 1005-15.
18. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48(1): 229-37.
19. Lee HY, Seong MW, Park SS, et al. Diagnostic accuracy of Xpert® MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis. Int J Tuberc Lung Dis 2013; 17(7): 917-21.
20. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40(2): 442-7.
21. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013; 13(1): 36-42.
22. Moure R, Martin R, Alcaidea F. Effectiveness of an integrated real-time PCR method for detection of the My-cobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol 2012; 50(2): 513-5.
23. Patel VB, Theron G, Lenders L, et al. Diagnostic accuracy of quantitative PCR (XPERT MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med 2013; 10(10): e1001536.
24. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us? Int J Tuberc Lung Dis 2012; 16(7): 860-70.